DAMPHOS BIOTECH INC.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
1. Quantitative rapid screening for infectious diseases in blood bags
2. Drug screening
3. Food safety screening
4. Feed additives: Providing solutions for PED, PRRS, AI, Salmonella, and Vibrio vulnificus
(The content above was translated by AI.)
2. Drug screening
3. Food safety screening
4. Feed additives: Providing solutions for PED, PRRS, AI, Salmonella, and Vibrio vulnificus
(The content above was translated by AI.)
Founded Year
2012
Unified Business No.
53940853
Status
Active
Number of Employees
0
Total Paid-in
Capital
46,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
DAMPHOS BIOTECH INC. is an ISO 13485:2016 certified supplier of in vitro diagnostics and high-end medical devices, owned by BPC Group International Global of the Republic of Seychelles. It has multiple offices and strategic partners worldwide. DAMPHOS BIOTECH INC. has established deep technical platforms with landmark universities and numerous scholars, enabling it to provide professional, miniaturized, and one-stop solutions.
Its proprietary material technology provides the world's smallest rapid diagnostic equipment for quantitative infectious viruses/pathogens, which is EU certified and meets the world's highest standards. Our specialty lies in the diagnosis of statutory infectious diseases such as HIV, syphilis, hepatitis B, and hepatitis C; the development of highly challenging dislocation chelation materials to solve difficult bacterial and viral problems in animals, poultry, and fisheries. The company is positioned as an upstream manufacturer, providing raw material and additive technical solutions, with its main markets in the United States, Taiwan, South Korea, Japan, Southeast Asia, and developing African countries.
(The content above was translated by AI.)
Its proprietary material technology provides the world's smallest rapid diagnostic equipment for quantitative infectious viruses/pathogens, which is EU certified and meets the world's highest standards. Our specialty lies in the diagnosis of statutory infectious diseases such as HIV, syphilis, hepatitis B, and hepatitis C; the development of highly challenging dislocation chelation materials to solve difficult bacterial and viral problems in animals, poultry, and fisheries. The company is positioned as an upstream manufacturer, providing raw material and additive technical solutions, with its main markets in the United States, Taiwan, South Korea, Japan, Southeast Asia, and developing African countries.
(The content above was translated by AI.)
